WO2008063113A8 - Cell -penetrating peptides and constructs containing them consisting 15-25 amino acids of tumor supressor protein p14arf or p19arf - Google Patents

Cell -penetrating peptides and constructs containing them consisting 15-25 amino acids of tumor supressor protein p14arf or p19arf Download PDF

Info

Publication number
WO2008063113A8
WO2008063113A8 PCT/SE2007/001017 SE2007001017W WO2008063113A8 WO 2008063113 A8 WO2008063113 A8 WO 2008063113A8 SE 2007001017 W SE2007001017 W SE 2007001017W WO 2008063113 A8 WO2008063113 A8 WO 2008063113A8
Authority
WO
WIPO (PCT)
Prior art keywords
cell
peptide
amino acids
penetrating peptides
p19arf
Prior art date
Application number
PCT/SE2007/001017
Other languages
French (fr)
Other versions
WO2008063113A1 (en
Inventor
Uelo Langel
Henrik Johansson
Samir El-Andaloussi
Original Assignee
Cepep Iii Ab
Uelo Langel
Henrik Johansson
Samir El-Andaloussi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cepep Iii Ab, Uelo Langel, Henrik Johansson, Samir El-Andaloussi filed Critical Cepep Iii Ab
Publication of WO2008063113A1 publication Critical patent/WO2008063113A1/en
Publication of WO2008063113A8 publication Critical patent/WO2008063113A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A cell-penetrating peptide or a construct comprising such a peptide of 15 to 25 amino acids comprising at least amino acids 1 - 14 of a mature mammalian tumor suppressor protein ARF or a scrambled or partially inverted sequence thereof, such as the human p14ARF protein SEQ ID NO:2, and the partially inverted sequence thereof SEQ ID NO: 1 optionally linked to one or more of a cargo, such as an anti-cancer drug, a detection marker, a cell-homing peptide, such as a tumor-homing peptide, a receptor ligand, a linker, and a peptide spacer comprising a selective protease cleavage site coupled to an inactivating peptide, is disclosed. The cell-penetrating peptides of the invention derived from ARF can either be biologically inert or have biological activity in themselves. Further, a method of delivering a cargo into a target cell in vivo or in vitro, is described.
PCT/SE2007/001017 2006-11-20 2007-11-19 Cell -penetrating peptides and constructs containing them consisting 15-25 amino acids of tumor supressor protein p14arf or p19arf WO2008063113A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US85993006P 2006-11-20 2006-11-20
SE0602459-0 2006-11-20
SE0602459 2006-11-20
US60/859,930 2006-11-20

Publications (2)

Publication Number Publication Date
WO2008063113A1 WO2008063113A1 (en) 2008-05-29
WO2008063113A8 true WO2008063113A8 (en) 2009-07-23

Family

ID=39429957

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2007/001017 WO2008063113A1 (en) 2006-11-20 2007-11-19 Cell -penetrating peptides and constructs containing them consisting 15-25 amino acids of tumor supressor protein p14arf or p19arf

Country Status (1)

Country Link
WO (1) WO2008063113A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016050934A1 (en) * 2014-10-02 2016-04-07 Aliophtha Ag Endosomal disentanglement of artificial transcription factors
US9822180B2 (en) 2012-02-28 2017-11-21 The University Of Birmingham Immunotherapeutic molecules and uses

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI121959B (en) * 2008-05-09 2011-06-30 Pirjo Laakkonen Peptide that targets brain tumors
US20130079382A1 (en) 2009-10-12 2013-03-28 Larry J. Smith Methods and Compositions for Modulating Gene Expression Using Oligonucleotide Based Drugs Administered in vivo or in vitro
WO2011084061A1 (en) 2010-01-08 2011-07-14 Universitair Medisch Centrum St. Radboud Cpp (cell penetrating peptide) and its uses
CA2797093C (en) 2010-04-26 2019-10-29 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-trna synthetase
EP2563381B1 (en) 2010-04-27 2017-08-09 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl trna synthetases
WO2011139853A2 (en) 2010-04-28 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases
US9034320B2 (en) 2010-04-29 2015-05-19 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Valyl-tRNA synthetases
AU2011248490B2 (en) 2010-04-29 2016-11-10 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Asparaginyl tRNA synthetases
US9034321B2 (en) 2010-05-03 2015-05-19 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-tRNA synthetases
CN103140233B (en) 2010-05-03 2017-04-05 Atyr 医药公司 Treatment, diagnosis and the discovery of antibody compositions related to the protein fragments of methionyl-tRNA synthetase
JP5976638B2 (en) 2010-05-03 2016-08-23 エータイアー ファーマ， インコーポレイテッド Innovative discovery of therapeutic, diagnostic and antibody compositions related to protein fragments of arginyl tRNA synthetase
AU2011248101B2 (en) 2010-05-04 2016-10-20 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-tRNA synthetase complex
EP2568996B1 (en) 2010-05-14 2017-10-04 aTyr Pharma, Inc. Therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases
AU2011258106B2 (en) 2010-05-27 2017-02-23 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-tRNA synthetases
EP2575857B1 (en) 2010-06-01 2018-01-24 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-trna synthetases
WO2012021247A2 (en) 2010-07-12 2012-02-16 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-trna synthetases
AU2011293294B2 (en) 2010-08-25 2016-03-24 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Tyrosyl-tRNA synthetases
CN103561771B (en) 2011-03-17 2019-01-04 伯明翰大学 The immunization therapy redirected
CN110251682B (en) 2011-11-24 2022-12-06 苏州宝时得电动工具有限公司 Polypeptide sequence design and application thereof in polypeptide-mediated siRNA delivery
CA2898148A1 (en) * 2012-10-05 2014-04-10 Eastern Virginia Medical School A family of synthetic polynucleotide-binding peptides and uses thereof
TW201441249A (en) * 2013-04-03 2014-11-01 Aliophtha Ag Artificial transcription factors and their use for the treatment of maladapted wound healing in the eye
AR095982A1 (en) 2013-04-03 2015-11-25 Aliophtha Ag GENETICALLY MODIFIED ARTIFICIAL TRANSCRIPTION FACTORS TO OVERCOME ENDOSOMIC ATTACK
EP3253419A1 (en) 2015-02-02 2017-12-13 The University of Birmingham Targeting moiety peptide epitope complexes having a plurality of t-cell epitopes
PT3377103T (en) 2015-11-19 2021-05-26 Revitope Ltd Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
KR102167755B1 (en) 2018-05-23 2020-10-19 주식회사 큐어바이오 Fragmented GRS polypeptide, mutants thereof and use thereof
CN109553659B (en) * 2018-11-26 2022-06-21 上海华新生物高技术有限公司 Cell penetrating peptide and transdermal interferon

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407062B1 (en) * 1995-09-27 2002-06-18 St. Jude Children's Research Hospital ARF-P19, a novel regulator of the mammalian cell cycle
US7339042B2 (en) * 2003-06-09 2008-03-04 University Of Florida Research Foundation, Inc. Gene delivery to tumors
KR20060054196A (en) * 2003-06-10 2006-05-22 주식회사 툴젠 Transducible dna-binding protein
US20060014712A1 (en) * 2004-05-30 2006-01-19 Cemines, Inc. Controlled delivery of therapeutic compounds

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9822180B2 (en) 2012-02-28 2017-11-21 The University Of Birmingham Immunotherapeutic molecules and uses
US10106621B2 (en) 2012-02-28 2018-10-23 The University Of Birmingham Immunotherapeutic molecules and uses
WO2016050934A1 (en) * 2014-10-02 2016-04-07 Aliophtha Ag Endosomal disentanglement of artificial transcription factors

Also Published As

Publication number Publication date
WO2008063113A1 (en) 2008-05-29

Similar Documents

Publication Publication Date Title
WO2008063113A8 (en) Cell -penetrating peptides and constructs containing them consisting 15-25 amino acids of tumor supressor protein p14arf or p19arf
EP1924601B1 (en) Expression of proteins in e.coli
CN101842109B (en) Peptides derivatized with A-B-C-D- and their therapeutical use
EP1966240B3 (en) Lactoferrin peptides useful as cell-penetrating peptides
EP2868744B1 (en) Screening method for peptide binding to target molecule in a ph-dependent manner
EP3059244B1 (en) C-met protein agonist
ES2343061T3 (en) DNA METHODS AND CONSTRUCTS FOR PRODUCTION OF HIGH PERFORMANCE POLYPEPTIDES.
US20020169125A1 (en) Recombinant production of polyanionic polymers and uses thereof
EP2570430A3 (en) Peptide vaccines with Seq ID No: 78, 41, 44, 46 or 48 for cancers expressing tumor-associated antigens
EP2351775B1 (en) Fusion protein comprising ubiquitin or ubiquitin-like protein, membrane translocation sequence and biologically active molecule and use thereof
CN107847583A (en) PEGylated Interleukin 10 for treating cancer
CA2766039A1 (en) Arginase formulations and methods
SK283485B6 (en) Parathormone derivatives, process for their production and pharmaceutical compositions containing them
CN106255699B (en) Cell penetrating peptides and methods of using the same to deliver biologically active substances
MX2007004116A (en) Vasoactive intestinal polypeptide pharmaceuticals.
US20130123199A1 (en) Protein complex for intracellular delivery and uses thereof
JP2005511614A (en) Novel epidermal growth factor protein and gene and method of use thereof
ES2627066T3 (en) Recombinant elastase proteins and their manufacturing and use procedures
CN107108712A (en) The method for improving recombinant protein yield
CN104039811A (en) Development of novel macromolecule transduction domain with improved cell permeability and method for using same
US20230203098A1 (en) Human transferrin receptor binding peptide
KR101898502B1 (en) Insulin-like growth factor 1 receptor binding peptides
Tran et al. Evaluation of efficient non-reducing enzymatic and chemical ligation strategies for complex disulfide-rich peptides
US20100041153A1 (en) Expression of Proteins in E. Coli
KR102274876B1 (en) Novel cell penetrating peptides and use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07835215

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07835215

Country of ref document: EP

Kind code of ref document: A1